A Double-Blind Randomized Placebo-Controlled Study to Assess the Safety Tolerability and Pharmacodynamics of SYNB8802 in Healthy Volunteers and in Patients with Enteric Hyperoxaluria

Brief description of study

SYNB8802 (the drug being tested) is a live biotherapeutic (biologicals) being developed as a potential treatment for enteric hyperoxaluria (EH). EH is a condition in which a person’s body does not properly absorb fat in the intestine, which leads to higher than normal levels of oxalate, a natural substance found in the human body and in many foods. High levels of oxalate can cause kidney stones and other, sometimes serious kidney conditions. People who have EH must follow a special diet to avoid foods that contain oxalate and fat, and they must take supplements (for example, calcium salts) to help the body get rid of extra oxalate. This study will include 2 parts. The information contained in this informed consent will focus on the second part of this study. Participants with EH will receive SYNB8802 at or below the highest dose that was tolerated in Part 1 or placebo (no active ingredient). Only Part 2 will be conducted at NYU to investigate whether it is safe and tolerable in EH participants.


Clinical Study Identifier: s20-02042
ClinicalTrials.gov Identifier: NCT04629170
Principal Investigator: Lama Nazzal.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.